Award Data

DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

DESCRIPTION provided by applicant There are greater than million patients that suffer end stage renal disease requiring hemodialysis Long term vascular access is vital for these patients to undergo hemodialysis and is obtained via surgical construction of an arteriovenous AV fistula or interposition of an AV graft Failure of vascular access results in staggering rate of morbidity and ev ...

DESCRIPTION (provided by applicant): Biological RNAs undergo extensive post-transcriptional modifications. These modifications are important in promoting the accuracy and efficiency of gene expression in biological systems. To decipher the functions of RNA modifications, robust analytical tools and methods that enable scientists to monitor, manipulate, and transcriptome-wide mapping RNA modificat ...

DESCRIPTION (provided by applicant): Paroxysmal Nocturnal Hemoglobinuria (PNH) is an orphan disease characterized by severe anemia, kidney and liver failure, and ultimately death, if left untreated. In 2007, FDA approved the first complement inhibitor, Eculizumab (Soliris(R)), for the treatment of PNH. Eculizumab binds to C5 and prevents C5 cleavage and the formation of C5b-9, a complement product ...

DESCRIPTION (provided by applicant): Each year, there are over 10,000 newborns diagnosed with hydrocephalus in the United States. Hydrocephalus, an excessive accumulation of cerebrospinal fluid (CSF) within the head, is a lifelong disease with no known cure. Fortunately, hydrocephalus can be managed with CSF shunts which redirect excessive CSF elsewhere in the body. Unfortunately, 30-40% o ...

DESCRIPTION (provided by applicant): This project aims to develop a novel nanofluidic-nanoplasmonic platform to realize multiplexed monitoring of biological binding processes, specifically for detection of cancer biomarkers in bio-fluids. In contrast to current large-sized, cumbersome surface plasmon resonance (SPR) sensing technology, the proposed device is comprised of a multilayer nanostructure ...

Abstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunodeficiency syndromes. Currently, myeloablative or irradiative conditioning regimens are used for enhancing HSC engraftment in transplantation, but they are often associated with significant morbidity a ...

DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...

DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's proprietary nanofiber culture scaffold (NANEX). Cancer stem cell research is of significant importance because, this approach has the potential to create an effective therapy that overcomes challenges o ...

DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designated Insulin-ZN, our product is a derivative of human insulin containing novel zinc-binding sites at the periphery of the insulin hexamer. The non-classical zinc-binding sites are mediated by paired (i ...